Analysts at UBS Maintained their Past ‘Buy’ rating on Shares Mallinckrodt (NYSE:MNK), Set a $70.0 Target

December 7, 2017 - By Ellis Scott

 Analysts at UBS Maintained their Past ‘Buy’ rating on Shares Mallinckrodt (NYSE:MNK), Set a $70.0 Target

Investors sentiment decreased to 0.72 in 2017 Q2. Its down 0.30, from 1.02 in 2017Q1. It fall, as 49 investors sold Mallinckrodt Public Limited Company shares while 136 reduced holdings. 37 funds opened positions while 96 raised stakes. 95.02 million shares or 0.42% more from 94.62 million shares in 2017Q1 were reported.

Guardian Life Ins Com Of America has 225 shares for 0% of their portfolio. Duncker Streett & Commerce Incorporated reported 0% stake. Parkside Fincl Bank & Trust reported 0% stake. Commonwealth National Bank Of Aus has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Cornerstone Cap Mngmt Holdings Lc invested in 0.01% or 17,085 shares. Hudock Capital Gru Ltd Liability Corp has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Pinebridge Investments Lp invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Goldman Sachs reported 1.06M shares. Victory Cap Mgmt reported 1,711 shares stake. Meyer Handelman holds 0.19% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 99,461 shares. Hartford stated it has 29,007 shares. Ls Advsrs Lc stated it has 7,489 shares or 0.02% of all its holdings. California Pub Employees Retirement System holds 0.02% or 237,000 shares. Valley Advisers Inc reported 0% stake. 70,642 are owned by Pggm Invests.

Mallinckrodt (NYSE:MNK) Rating Reaffirmed

They currently have a $70.0 TP on Mallinckrodt (NYSE:MNK). The target price by UBS would suggest a potential upside of 229.41 % from the company’s last close price. This has been disclosed to clients in an analyst report on 6 October.

Investors sentiment decreased to 0.72 in 2017 Q2. Its down 0.30, from 1.02 in 2017Q1. It fall, as 49 investors sold Mallinckrodt Public Limited Company shares while 136 reduced holdings. 37 funds opened positions while 96 raised stakes. 95.02 million shares or 0.42% more from 94.62 million shares in 2017Q1 were reported.

Guardian Life Ins Com Of America has 225 shares for 0% of their portfolio. Duncker Streett & Commerce Incorporated reported 0% stake. Parkside Fincl Bank & Trust reported 0% stake. Commonwealth National Bank Of Aus has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Cornerstone Cap Mngmt Holdings Lc invested in 0.01% or 17,085 shares. Hudock Capital Gru Ltd Liability Corp has invested 0% in Mallinckrodt Public Limited Company (NYSE:MNK). Pinebridge Investments Lp invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Goldman Sachs reported 1.06M shares. Victory Cap Mgmt reported 1,711 shares stake. Meyer Handelman holds 0.19% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK) for 99,461 shares. Hartford stated it has 29,007 shares. Ls Advsrs Lc stated it has 7,489 shares or 0.02% of all its holdings. California Pub Employees Retirement System holds 0.02% or 237,000 shares. Valley Advisers Inc reported 0% stake. 70,642 are owned by Pggm Invests.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 21 analysts covering Mallinckrodt (NYSE:MNK), 9 have Buy rating, 0 Sell and 12 Hold. Therefore 43% are positive. Mallinckrodt has $218 highest and $24.0 lowest target. $69.42’s average target is 226.68% above currents $21.25 stock price. Mallinckrodt had 86 analyst reports since August 5, 2015 according to SRatingsIntel. On Friday, October 9 the stock rating was initiated by Mizuho with “Neutral”. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Jefferies on Thursday, June 29. The rating was maintained by Stifel Nicolaus on Friday, August 4 with “Buy”. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Deutsche Bank on Wednesday, October 7. Barclays Capital maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating on Tuesday, October 13. Barclays Capital has “Overweight” rating and $80 target. The rating was maintained by Deutsche Bank on Wednesday, August 31 with “Buy”. BMO Capital Markets maintained Mallinckrodt Public Limited Company (NYSE:MNK) rating on Friday, September 4. BMO Capital Markets has “Market Perform” rating and $106.0 target. BMO Capital Markets maintained the stock with “Buy” rating in Wednesday, August 16 report. As per Wednesday, December 7, the company rating was reinitiated by Oppenheimer. Northland Capital initiated Mallinckrodt Public Limited Company (NYSE:MNK) on Wednesday, November 11 with “Outperform” rating.

The stock decreased 0.47% or $0.1 during the last trading session, reaching $21.25. About 2.24M shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 30.39% since December 7, 2016 and is downtrending. It has underperformed by 47.09% the S&P500.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $2.02 billion. The companyÂ’s Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It currently has negative earnings. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

More notable recent Mallinckrodt Public Limited Company (NYSE:MNK) news were published by: Streetinsider.com which released: “Wells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform” on November 08, 2017, also Streetinsider.com with their article: “Mallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray” published on November 08, 2017, Seekingalpha.com published: “Mallinckrodt: Where Does It Go From Here?” on November 09, 2017. More interesting news about Mallinckrodt Public Limited Company (NYSE:MNK) were released by: Seekingalpha.com and their article: “Why Mallinckrodt Cratered” published on November 13, 2017 as well as Prnewswire.com‘s news article titled: “Mallinckrodt plc Presents Health Economic Data on Management of Infantile …” with publication date: December 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.